Introduction
Accumulating clinical and experimental evidence has been gathered over the past few years associating neuroinflammation with epilepsy and/or increased seizure susceptibility. In line with this view, while acute and chronic seizures increase key inflammatory mediators in the brain (Vezzani and Granata, 2005) , inflammatory mediators synthesized and released in response to pathogen and tissue damage facilitate seizures (Gomez et al., 2014; Ho et al., 2015) .
Inflammation, as part of the innate immune response, is commonly described as sequential events triggered by the activation of patternrecognition receptors by pathogen-and damage-associated molecular patterns, such as the Toll-like receptors (TLRs) (Maroso et al., 2010) . The activation of TLRs leads to the induction of numerous genes that function in inflammatory responses. These include cytokines (e.g., tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β) and interleukin-6 (IL-6)), inflammatory chemokines, such as CCL2 (Cazareth et al., 2014) and, sequentially, key enzymes involved in the synthesis of proinflammatory lipid mediators and nitric oxide (Hsiao et al., 2007) . Accordingly, TNF-α induces prostaglandin G/H synthase-2 in microvascular vessels and infiltrating neutrophils (Tsao et al., 1999) and IL-1β stimulates prostaglandin E 2 (PGE 2 ) production in murine astrocytes (O'Banion et al., 1996) . Cyclooxygenases (COXs) 1 and 2 convert arachidonic acid to PGH 2 , and specific thromboxane or PG synthases convert PGH 2 to thromboxane A 2 (TXA 2 ), PGF 2α , PGE 2 , PGI 2 or PGD 2 (Medeiros et al., 2012) .
While this sequential view of the inflammatory process (TLR activation, cytokine synthesis, lipid mediator production) has been relatively well established for the peripheral production of prostanoids (Kawai and Akira, 2008) and lipopolysaccharide (LPS)-induced neuroinflammation (Chu et al., 2015; Ho et al., 2015) , there is evidence that the prostaglandins produced in response to seizures are initially synthesized by cytokine-independent mechanisms, which involve constitutive COX-2 (involved in PGF 2α , PGE 2 , 6-keto-PGF 1α , TXA 2 and PGD 2 production) and COX-1 (involved in PGD 2 and TXA 2 production) (Choi et al., 2009) . Therefore, the sequential production of cytokines and prostaglandins that has consolidated in the literature as a logical sequence for the peripheral inflammatory response, may not occur exactly in the same way in the central nervous system (CNS). As a consequence, it is possible that constitutive COX-2-derived prostaglandins modulate seizure-induced cytokine production and release in the CNS. This would be particularly relevant considering the well-known proconvulsant action of TNF-α (Zare-Shahabadi et al., 2015) , IL-1β (Arisi et al., 2015; Balosso et al., 2008) and IL-6 (Campbell et al., 1993) . If prostaglandins increased proconvulsant (or decreased anticonvulsant) cytokine production and release, this could constitute an additional mechanism by which proconvulsant prostaglandins, such as PGE 2 (Oliveira et al., 2008a (Oliveira et al., , 2008b , facilitate seizures. This putative feedforward proinflammatory and proconvulsant mechanism would sum to the already described PGE 2 -induced increase of astrocytic glutamate release (Takemiya et al., 2003) , Na + ,K + -ATPase activity inhibition (Oliveira et al., 2009 ) and inhibition of potassium currents (Chen and Bazan, 2005) in the CNS. Therefore, in this study we investigated whether different COX-2 inhibitors alter pentylenetetrazol (PTZ)-induced seizures and increase of IL-1β, IL-6, interferon-γ (INF-ɣ), TNF-α, and IL-10 levels in mice.
Materials and methods

Animals
Adult male Swiss mice (28 ± 3 g; n = 168), housed ten to a cage, and maintained under controlled light and environment (12-h light/ dark cycle, lights on at 7:00, 22 ± 1°C, 55% relative humidity) with free access to food (Guabi, Santa Maria, Brazil) and water were used. All animals were obtained from the Animal House of the Federal University of Santa Maria. Behavioral tests were conducted during the light phase of the cycle (between 10:00 a.m. and 14:00 p.m.). All experiments reported in this study were conducted in accordance with the policies of the National Institutes of Health Guide for the Care and Use of Laboratory Animals (NIH Publications no. 80-23), revised in 1996, and with the Institutional and National regulations for animal research (#024/2014). All efforts were made to reduce the number of animals used to a minimum, as well as to minimize their suffering.
Reagents
The following drugs were used in the present study. PTZ (Sigma, USA), nimesulide (Nisulid©, Aché), celecoxib (Celebra©, Pfizer) or etoricoxib (Arcoxia©, MSD). Commercial ELISA (enzyme-linked immunosorbent assay) kits for cytokines assays were purchased from eBIOSCIENCE (San Diego, USA). PTZ was dissolved in 0.9% NaCl and administered intraperitoneally (i.p.). Nimesulide, celecoxib and etoricoxib were suspended in 0.1% carboxymethylcellulose (CMC) plus 5% Tween 80 and administered by oral gavage (volume: 10 ml/kg).
Experimental protocol: effect of nimesulide, celecoxib or etoricoxib on PTZ-induced seizures
Since the three COX-2 inhibitors permeate the blood-brain barrier (Dembo et al., 2005; Ferrario and Bianchi, 2003; Renner et al., 2010) and their IC 50 s are similar (around 1 µM) (Shi and Klotz, 2008) , the effect of nimesulide, celecoxib or etoricoxib on PTZ-induced seizures was investigated by oral administering each drug (0.2, 2 or 20 mg/kg in 0.1% CMC in 5% Tween 80), or vehicle (0.1% CMC in 5% Tween 80, 10 ml/kg) 60 min before PTZ (50 mg/kg, i.p.). After PTZ injection animals were observed for the appearance of behavioral seizures, as described below. PTZ has been widely used as a model of acute seizure and drug doses were chosen based on previous studies (Dhir et al., 2006; Jayaraman et al., 2010; Oliveira et al., 2008b; Salvadori et al., 2012) .
Seizure evaluation
After PTZ injection the animals were followed up (and video monitored) for 20 min and the latency to myoclonic jerks and generalized tonic-clonic seizures were recorded, according to Ferraro et al. (1999) . The severity of PTZ-induced seizures was scored by a modified Racine scale (Luttjohann et al., 2009) , as follows: (1) sudden behavioral arrest and/or motionless staring; (2) facial jerking with muzzle or muzzle and eye; (3) neck jerks; (4) clonic seizure in a sitting position; (5) convulsion including clonic and/or tonic-clonic seizure while lying on the belly and/or pure tonic seizure; (6) convulsion including clonic and/or tonic-clonic seizure while lying on the side and/or wild jumping. We have considered the current experimental model as a model of acute individual seizure (but not a model of status epilepticus) because the Commission on Classification and Terminology and the Commission on Epidemiology of the International League Against Epilepsy (ILAE) defined status epilepticus (SE) as "… a condition resulting either from the failure of the mechanisms responsible for seizure termination or from the initiation of mechanisms, which lead to abnormally, prolonged seizures (after time point t1). It is a condition, which can have long-term consequences (after time point t2), including neuronal death, neuronal injury, and alteration of neuronal networks, depending on the type and duration of seizures. This definition is conceptual, with two operational dimensions: the first is the length of the seizure and the time point (t1) beyond which the seizure should be regarded as "continuous seizure activity." The second time point (t2) is the time of ongoing seizure activity after which there is a risk of longterm consequences. In the case of convulsive (tonic-clonic) SE, both time points (t1 at 5 min and t2 at 30 min) are based on animal experiments and clinical research" (Trinka et al., 2015) . Since our animals did not achieve 5 min of continuous seizure activity, it is not possible to classify their seizures as "status epilepticus".
Cytokine assay
Animals were treated with vehicle (0.1% CMC in 5% Tween 80, p.o., 10 ml/kg) or nimesulide (20 mg/kg) or celecoxib (20 mg/kg) or etoricoxib (20 mg/kg) by oral gavage and, 60 min thereafter were injected with PTZ (50 mg/kg, i.p.) or 0.9% NaCl (10 ml/kg, i.p.). Animals were killed by decapitation 20 min after PTZ (or 0.9% NaCl) injection and the hippocampi and cerebral cortex were dissected and homogenized in 10 mM PBS containing 1 mM ethylenediaminetetraacetic acid, 0.1 mM phenylmethylsulfonyl fluoride and 0.5% bovine serum albumin, pH 7.4. Samples were centrifuged at 25,000g for 10 min and the supernatant was used to measure IL-1β, IL-6, TNF-α, INF-ɣ and IL-10 levels. Cytokine quantification was carried out using a commercial ELISA kit (eBIOSCIENCE, San Diego, USA, IL-1β cat. BMS6002INST; IL-6 cat. BMS603HS; TNF-α cat. BMS6072INST; INF-ɣ cat. BMS606INST; IL-10 cat. BMS614INST), according to manufacturer's instructions. The results were expressed as picogram of cytokine per milligram of protein. Protein content was measured by the bicinchoninic acid method (Pierce, Rockford, IL).
Statistical analyses
Behavioral data were analyzed by Kruskal-Wallis test followed by nonparametric Dunn's multiple comparison test. These data are presented as median (n = 8-12) and interquartile range. Cytokine levels were analyzed by three-way ANOVA: pretreatment (vehicle or COX-2 inhibitor) by treatment (saline or PTZ) by cerebral structure (hippocampus or cerebral cortex, considered as within-subject factor) followed by Bonferroni post hoc test and are expressed as mean (n = 3-5) + S.E.M. A probability of P < 0.05 was considered significant. The number of animals in each group is small because of the restrictions imposed by the ethics and animal care committee and animal use guidelines, which includes the use of factorial designs (Festing and Altman, 2002) and other measures aiming rational use of animals. We have used the strategy of sequential sampling, in which an experiment may be interrupted if a significant effect is found in a planned statistical analysis of partial data (before the estimated n by power analysis is achieved) because we did not have information about the variability of the dependent variables (Chamove, 1996) . We have estimated a n=8 per group using the G Power software for these experiments. As far as we found statistically significant effects using the first batch of animals (3-5 per group -the experiment was planned to occur using two batches of animals), the experiment was interrupted.
Results
Effect of nimesulide, celecoxib or etoricoxib on PTZ-induced seizures
Statistical analysis revealed that nimesulide significantly increased the latency to PTZ-induced myoclonic jerks [H(3) = 11.63, P < 0.05, On the other hand, celecoxib and etoricoxib did not alter PTZ-induced seizures and Racine scale scores (Figs. 2 and 3, respectively). Two animals died in vehicle-PTZ groups (2/30), one animal in 0.2 mg/Kg celecoxib-PTZ group (1/12) and one animal in 2 mg/Kg etoricoxib-PTZ group (1/10) due to PTZ-induced seizures. These animals were not used for cytokine assays.
Supplementary material related to this article can be found online at http://dx.doi.org/10.1016/j.ejphar.2017.05.013.
Effect of nimesulide on cytokine (IL-1β, IL-6, INF-ɣ, TNF-α and IL-10) levels
Statistical analysis of IL-1β levels [three-way ANOVA: pretreatment (vehicle or nimesulide) by treatment (saline or PTZ) by cerebral structure (hippocampus or cerebral cortex)] revealed a significant treatment (saline or PTZ) by cerebral structure interaction [F(1,11) = 20.63, P < 0.001]. Post hoc analysis (Bonferroni's test) showed that PTZ consistently increased IL-1β levels in both cerebral structures (Fig. 4A ). Statistical analysis of IL-6 levels revealed significant pretreatment (vehicle or nimesulide) by structure (hippocampus or cerebral cortex) and treatment (saline or PTZ) by structure (hippocampus or cerebral cortex) interactions: [F(1,11) = 15.82, P < 0.002 and F(1,11) = 23.58, P < 0.001, respectively]. Post hoc analysis revealed that PTZ consistently increased IL-6 levels in both cerebral structures. Post hoc analysis (individual Bonferroni tests within each cerebral structure) also showed that nimesulide decreased IL-6 levels in the cerebral cortex of animals that received PTZ (Fig. 4B ). Statistical analysis of IFN-ɣ levels revealed significant pretreatment (vehicle or nimesulide) by structure (hippocampus or cerebral cortex) and treatment (saline or PTZ) by structure (hippocampus or cerebral cortex) interactions: [F(1,11) = 12.61, P < 0.005 and F(1,11) = 7.68, P < 0.018, respectively]. The post-hoc analysis revealed PTZ consistently increased IFN-ɣ levels in both cerebral structures. Post hoc analysis (individual Bonferroni tests within each cerebral structure) also revealed that nimesulide decreased IFN-ɣ levels in the cerebral cortex, regardless the animals received saline or PTZ (Fig. 4C) . The statistical analysis of TNF-α levels revealed significant pretreatment (vehicle or nimesulide) by structure (hippocampus or cerebral cortex) and treatment (saline or PTZ) by structure (hippocampus or cerebral cortex) interactions: [F(1,11) = 6.50, P < 0.027 and F(1,11) = 14.15, P < 0.003, respectively]. The post-hoc analysis revealed PTZ consistently increased TNF-α levels in both cerebral structures (Fig. 4D) and that nimesulide decreased TNF-α levels in the cerebral cortex, regardless the animals received saline or PTZ. Statistical analysis of IL-10 levels revealed a significant pretreatment (vehicle or nimesulide) by treatment (saline or PTZ) interaction [F(1,11) = 18.31, P < 0.001]. Post hoc analysis (Bonferroni's test) showed that PTZ consistently increased IL- 
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Effect of celecoxib on cytokine (IL-1β, IL-6, INF-ɣ, TNF-α and IL-10) levels
Statistical analysis [three-way ANOVA: pretreatment (vehicle or celecoxib) by treatment (saline or PTZ) by cerebral structure (hippocampus or cerebral cortex)] of IL-1β levels revealed significant effects of pretreatment [F(1,10) = 27.94, P < 0.001], treatment [F(1,10) = 222.98, P < 0.001] and cerebral structure [F(1,10) = 47.88, P < 0.001]. Post hoc analysis (Bonferroni's test) showed that while celecoxib decreased in cerebral cortex, PTZ increased IL-1β levels, regardless of the cerebral structure analyzed. Moreover, IL-1β levels were higher in the cerebral cortex than in the hippocampus (Fig. 5A) . The same profile was found for IL-6 [significant effects of pretreatment: F(1,10) = 33.98, P < 0.001; treatment: F(1,10) = 355.44, P < 0.001; and cerebral structure F(1,10) = 35.00, P < 0.001] (Fig. 5B ) and for INF-ɣ [significant effects of pretreatment: F(1,10) = 30.47, P < 0.001; treatment: F(1,10) = 347.15, P < 0.001; and cerebral structure F(1,10) = 82.47, P < 0.001] (Fig. 5C) . Interestingly, statistical analysis of TNF-α levels revealed significant pretreatment (vehicle or celecoxib) by structure (hippocampus or cerebral cortex) and treatment (saline or PTZ) by structure (hippocampus or cerebral cortex) interactions: [F(1,10) = 8.74, P < 0.05 and F(1,10) = 42.16, P < 0.001, respectively]. Post hoc analysis (individual Bonferroni tests within each cerebral structure) revealed that celecoxib decreased TNF-α levels in the cerebral cortex, regardless the animals received saline or PTZ, and that celecoxib reduced hippocampal TNF-α levels only in those animals injected with PTZ. The post-hoc analysis also revealed that PTZ-induced increase of TNF-α levels was more prominent in the cerebral cortex than in the hippocampus (Fig. 5D ). Statistical analysis of IL-10 also revealed significant pretreatment (vehicle or celecoxib) by structure (hippocampus or cerebral cortex) and treatment (saline or PTZ) by structure (hippocampus or cerebral cortex) interactions: [F(1,10) = 12.99, P < 0.05 and F(1,10) = 49.85, P < 0.05, respectively]. Post hoc analysis (individual Bonferroni tests within each cerebral structure) revealed that celecoxib increased IL-10 levels only in the cerebral cortex of animals injected with PTZ (Fig. 5E ).
3.4. Effect of etoricoxib on cytokine (IL-1β, IL-6, INF-ɣ, TNF-α and IL-10) levels Statistical analysis of IL-1β levels [three-way ANOVA: pretreatment (vehicle or etoricoxib) by treatment (saline or PTZ) by cerebral structure (hippocampus or cerebral cortex)] revealed a significant pretreatment (vehicle or etoricoxib) by treatment (saline or PTZ) interaction [F(1,10) = 5.32, P < 0.05]. Post hoc analysis (Bonferroni's test) showed that etoricoxib decreased IL-1β levels in the cerebral cortex of the animals injected with saline (but not in those injected with PTZ). A similar tendency towards an effect of etoricoxib on the levels IL-1β in the hippocampus of the animals injected with saline was also found, but did not achieve statistical 
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European Journal of Pharmacology 810 (2017) 15-25 significance. In addition, significant effects of treatment (saline or PTZ) [F(1,10) = 81.18, P < 0.001] and cerebral structure [F(1,10) = 5.23, P < 0.05] were revealed in the analysis because PTZ consistently increased IL-1β levels regardless the pretreatment and because IL-1β levels were higher in the cerebral cortex than in the hippocampus (Fig. 6A ). Statistical analysis of IL-6 data revealed significant effects of treatment: [F(1,10) = 120.56, P < 0.001]. Post hoc analysis (Bonferroni's test) showed that PTZ consistently increased IL-6 levels regardless of the cerebral structure analyzed. In addition, analogously to the results with IL-1β, etoricoxib decreased IL-6 levels in the cerebral cortex of animals injected with saline (Fig. 6B ). Statistical analysis of INF-ɣ levels revealed significant effects of pretreatment: [F(1,10) = 12.08, P < 0.006] and treatment: [ F(1,10) = 192.79, P < 0.001]. Post hoc analysis (Bonferroni's test) showed that PTZ consistently increased INF-ɣ levels in both cerebral structures and that etoricoxib decreased INF-ɣ levels in the cerebral cortex per se (Fig. 6C ). Statistical analysis of TNF-α levels revealed significant effects of pretreatment: [F(1,10) = 10.50, P < 0.009] and treatment: [F(1,10) = 158.28, P < 0.001]. Post hoc analysis (Bonferroni's test) showed that PTZ consistently increased TNF-α levels in both cerebral structures and that etoricoxib decreased TNF-α levels in the cerebral cortex of animals that received saline (Fig. 6D) . Statistical analysis of IL-10 levels revealed significant pretreatment (vehicle or etoricoxib) and treatment (saline or PTZ): [F(1,10) = 10.82, P < 0.008 and F(1,10) = 262.13, P < 0.001, respectively]. Post hoc analysis (individual Bonferroni tests within each cerebral structure) revealed that PTZ consistently increased IL-10 levels in both cerebral structures. Only a tendency towards a significant effect on etoricoxib on IL-10 levels in the cerebral cortex of saline- 
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injected animals was found (P = 0.07, Bonferroni's test) (Fig. 6E ).
Discussion
The current study showed that while nimesulide attenuated, celecoxib and etoricoxib did not alter PTZ-induced seizures in mice. Other remarkable finding of this study is the prominent PTZ-induced increase of IL-1β, IL-6, INF-ɣ, TNF-α and IL-10 levels in both cerebral cortex and hippocampus. While celecoxib and nimesulide attenuated PTZ-induced increase of proinflammatory cytokines, etoricoxib did not. Nimesulide was the only COX-2 inhibitor that increased IL-10 levels in the cerebral cortex and in the hippocampus, and such an increase depended on PTZ administration.
Over the past few years an increasing body of clinical and experimental evidence has strongly supported the hypothesis that inflammation may constitute a common and key mechanism in the pathophysiology of seizures (Vezzani and Granata, 2005) . In fact, it has been shown that several convulsant agents or procedures, regardless of their nature, increase cytokine levels. Accordingly, kainic acid, pilocarpine, PTZ, bicuculline, 4-aminopyridine and electric and auditory stimulation increase the levels of cytokines, measured as mRNA or protein, in different cerebral structures (Abdallah, 2010; Al-Shorbagy et al., 2013; Arisi et al., 2015; Balosso et al., 2008; Chiu et al., 2015; De Simoni et al., 2000; de Souza Bernardino et al., 2015; Gomez et al., 2014; Lima et al., 2015; Minami et al., 1991 Minami et al., , 1990 Rodriguez et al., 2015; Vezzani et al., 1999) , although a decrease in IL-1β and IL-10 levels was observed 4 h after scorpion venom-induced seizures. Table 1 summarizes the main findings of these studies. A comprehensive analysis of the data contained in Table 1 suggests that cytokine levels increase depends on the method used to induce seizures (including nature of the convulsant agent and route of administration). A second interesting finding is that the more recent studies have shown an early increase in cerebral tissue levels of cytokines after seizures, as early as 20-30 min after seizure induction (Al-Shorbagy et al., 2013; Gomez et al., 2014) . This is in line with the view that post-transcriptional events, such as mRNA processing and translation, may regulate cytokine levels in the early steps of inflammation (Mino and Takeuchi, 2013) . Therefore, our findings are in full agreement with the studies which have reported an early increase of brain cytokine levels after PTZ-induced seizures (Al-Shorbagy et al., 2013; Gomez et al., 2014) and with the studies that have indicated a role for cytokines in seizure induction in animals that genetically under-or overexpress cytokines (Campbell et al., 1993; Claycomb et al., 2012; Vezzani et al., 1999 ).
Etoricoxib did not alter PTZ-induced seizures or cytokine levels in both cerebral cortex and hippocampus of mice in our study. There are only a few studies on the effect of etoricoxib on experimental models of seizures (Citraro et al., 2015; Jayaraman et al., 2010; Katyal et al., 2015) , and both anticonvulsant and proconvulsant effects have been reported, depending on the dose used. Moreover, etoricoxib potentiates the anticonvulsant effect of diazepam but decreases the anticonvulsant effect of phenytoin (Jayaraman et al., 2010) . Since these studies have used different administration protocols, animal species and convulsant agents, it is possible that these methodological differences may have accounted for the these discrepant outcomes, including the currently lack of effect of etoricoxib on PTZ-induced seizures in our assay.
Celecoxib decreased the levels of all proinflammatory cytokines: IL-1β, IL-6, INF-ɣ, TNF-α. Although a proconvulsant role has been Table 1 Cytokine levels at different time-points, brain regions and seizure models. European Journal of Pharmacology 810 (2017) 15-25 attributed to these cytokines (Abdallah, 2010; Arisi et al., 2015; De Simoni et al., 2000; Rodriguez et al., 2015) , it seems that the celecoxibinduced decrease of their absolute cortical and hippocampal levels was not enough to decrease seizure susceptibility in mice. In fact, since celecoxib decreased basal levels of these cytokines, the PTZ-induced increase of their levels (in terms of respective control-fold values) was not altered by celecoxib. The same applies to the anti-inflammatory cytokine IL-10. Therefore, one might argue that the effects of celecoxib on proinflammatory cytokines and on IL-10 were not specific for PTZinduced effects. Similarly to celecoxib, nimesulide decreased the absolute levels of proinflammatory cytokines, only in the cerebral cortex. On the other hand, nimesulide selectively increased IL-10 levels in the cerebral cortex and hippocampus of those animals that received PTZ, constituting the only variable that was differentially altered by nimesulide in PTZ-treated animals and that, consequently, might be associated with an increased latency to develop seizures. IL-10 is a well-known anti-inflammatory cytokine that diminishes immune responses under different inflammatory scenarios (Glocker et al., 2011) . Its anti-inflammatory properties have been attributed to the inhibition of antigen-presenting cell function and suppression of the production of proinflammatory cytokines and chemokines (O'Garra et al., 2008) . Accordingly, IL-10 inhibits the production of the proinflammatory cytokines IL-1β, IL-6, and TNF-α (Leon et al., 1998) and promotes inflammation resolution within the periphery and the CNS (Saraiva and O'Garra, 2010) by deactivating macrophages which, in turn, decrease T cells cytokine production (Youn et al., 2013) . Accumulating evidence also supports an anticonvulsant role for IL-10, since it protects against the development of epileptiform activity evoked by transient episodes of hypoxia in rat hippocampal slices (Levin and Godukhin, 2007) and suppresses the development of focal ictal discharges induced by kindling (Godukhin et al., 2009 ). In addition, GFAP-IL10Tg mice, which overexpress astrocyte-derived IL-10, present a lower excitability of the CA3-CA1 synapses (Almolda et al., 2015) . The finding that nimesulide increases IL-10 production agrees with the findings that COX-2 derived PGE 2 inhibits LPS-induced IL-10 production through EP2 (prostaglandin E type 2 receptor)-mediated activation in microglia. Furthermore, interruption of COX-2 function by NS-398 and Dup-697 and deletion of the COX-2 gene enhance LPS-induced IL-10 production by microglia (Chu et al., 2015) . Therefore, it is possible that the currently described anticonvulsant effect of nimesulide is due to the prominent rapid increase in the hippocampal and cortical levels of IL-10. In this context, it is important to point out that IL-10 mRNA stability is a key component in the regulation of the levels of this cytokine. In fact, multiple copies of potential mRNA destabilizing motifs are found in the 3ʹ untranslated region (UTR) of IL-10 mRNA. Several stimuli, such as p38, STAT-3, and adenosine receptor activation induce IL-10 mRNA stabilization and increase IL-10 production in a few minutes (Tudor et al., 2009 ). In addition, there is also evidence that microRNAs can rapidly upregulate both mRNA and protein expression of IL-10 (Ma et al., 2010) . We acknowledge that our experimental design does not allow concluding whether the decrease in cytokine levels is a cause or a consequence of seizures, particularly for proinflammatory (and proconvulsant) cytokines. However, this does not seem to be the case for IL-10. Since PTZ/ nimesulide-treated animals presented less seizures and increased levels of IL-10 compared with PTZ/saline-treated animals, the increased levels of IL-10 cannot be explained by increased seizure activity. Even considering this point, we acknowledge that our evidence of the involvement of IL-10 is circumstantial and that more experiments are necessary to define whether IL-10 itself or other metabolite/factor/ target(s) is(are) mediating the currently described anticonvulsant effect of nimesulide. In fact, a number of studies suggest that nimesulide has effects other than the well-described inhibition of PGs synthesis in various cell types (Di Battista et al., 1999; Goncalves et al., 2010; Niranjan et al., 2012; Pelletier and Martel-Pelletier, 1993; Pelletier et al., 1997) . Pelletier et al. (1997) , using human osteoarthritic synovial fibroblasts in culture, showed that therapeutic concentrations of nimesulide reduce the synthesis of urokinase and IL-6, increase the production of plasminogen activator inhibitor-1 and suppress matrix metalloproteinase synthesis by cartilage explants in vitro (Pelletier and Martel-Pelletier, 1993) . Nimesulide prevents the LPS-induced elevation of TNF-α and PGE 2 in brain glial cultures (Shemi et al., 2000) , downregulates 1-methyl-4-phenyl 1,2,3,6 tetrahydropyridine-induced TNF-α and IL-1β expression in rat C6 astrocytoma cells (Niranjan et al., 2012) and suppresses neurogenesis in the adult mouse brain, possibly by microglia-mediated mechanisms (Goncalves et al., 2010) . Moreover, nimesulide modulates glucocorticoid receptor (GR) activity possibly by activating downstream mitogen-activated protein kinase and subsequent phosphorylation and activation of the GR (Di Battista et al., 1999) . Therefore, we cannot rule out the involvement of these mechanisms in the currently described anti-inflammatory and anticonvulsant effects of nimesulide. Previous studies have proposed, based on the evaluation of prototype COX-2 inhibitors, that this pharmacological class might inhibit (Dhir et al., 2006; Oliveira et al., 2008b) , facilitate (Claycomb et al., 2012) or have no effect on seizures (Claycomb et al., 2011) . Briefly, as carefully discussed in recent reviews, the effect of COX-2 inhibitors on seizures may vary depending on the convulsant stimulus, the drug dose, the timing and route of administration, and the species (mouse or rat) used (Dey et al., 2016) . In line with this view, while we have previously reported that celecoxib biphasically decreases PTZ-induced seizures in rats (Oliveira et al., 2008b) , such an anticonvulsant effect was not confirmed in a different species (Mus musculus -of the albino Swiss strain, which was used in the current study).
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At last, while it is fairly known that nimesulide, celecoxib and etoricoxib cross the blood-brain barrier (Dembo et al., 2005; Ferrario and Bianchi, 2003; Renner et al., 2010) , we cannot rule out that pharmacokinetic differences among these drugs may have accounted for the currently described differential effects of these drugs on seizures and cytokine levels, even considering that three doses of the different COX-2 inhibitors were used in the current study to overcome this limitation.
Conclusions
PTZ induces seizures and early increase of cytokine levels in the cerebral cortex and hippocampus. Nimesulide decreases PTZ-induced seizures and proinflammatory cytokine increase. Moreover, it increases cortical and hippocampal levels of IL-10 in PTZ-injected animals, constituting circumstantial evidence that IL-10 increase may be involved in the anticonvulsant effect of nimesulide. Although the COX-2 inhibitors etoricoxib and celecoxib decrease proinflammatory cytokine levels, they do not alter PTZ-induced increase of cytokine levels or PTZ-induced seizures. Our data suggest that a pharmacological class effect of COX-2 inhibitors on seizures in mice is unlikely.
